Nanotechnologie - Noch kann man einsteigen :-)
Seite 5 von 7 Neuester Beitrag: 25.04.21 13:23 | ||||
| Eröffnet am: | 08.05.03 00:31 | von: Dr.UdoBroem. | Anzahl Beiträge: | 155 |
| Neuester Beitrag: | 25.04.21 13:23 | von: Nicoleyiwga | Leser gesamt: | 115.163 |
| Forum: | Börse | Leser heute: | 9 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | 4 | | 6 | 7 > | ||||
Jetzt werden mal so nebenbei 2 Millionen neue Aktien platziert und der Kurs hat sich nichtsdestotrotz in ein paar Tagen fast verdoppelt...
Ein gutes Gefühl habe ich dabei nicht mehr.
The technology Tegal supports may be an alternative to the memory found in most computer devices... The co is small, but sales in SepQ grew 20% to $3.2 mln.and more importantly, the co is approaching profitability, reporting a non-GAAP loss of $(0.08) vs $(0.33) a year ago. Mkt cap $52 mln, 15.5 mln float, 808K avg daily volume.
BEI DEN JÜNGSTEN TOP EMPFEHLUNGEN SIND U.A. WESTAIM (WEDX), NANOGEN (NGEN) und ALTAIR (ALTI). DIE TREFFERQUOTE DER STUDIE IST BEEINDRUCKEND. ICH HABE AUF DEREN BASIS SCHON 245 % PERFORMANCE ERZIELT.
Diese Studie kann beim Wirtschaftsmagazin GEWINN unter www.gewinn.com (gewinn@gewinn.com) bestellt werden.
Ich werde jedenfalls mal ausnahmsweise mit stoploss arbeiten. Da ist jetzt soviel Gewinn aufgelaufen. Wie lange läuft das noch, was denkt ihr?
Gruß BarCode
andererseits gibt es auch stimmen, die vor einer zunehmenden roboterisierung warnen...
Sniffing For Anthrax
Friday January 9, 3:52 pm ET
Little-known Cepheid (NasdaqNM:CPHD - News) has caught the eye not only of traders but also of long-term big investors. Its shares rocketed from 4 in August to 10.50 on Jan. 5. (The stock was featured in this column on Sept. 23, 2002, at 3.74.) "Despite the runup, the stock is way undervalued," says Elemer Piros of Rodman & Renshaw, who sees it at 17 in a year.
The U.S. Postal Service has signed up Cepheid to install
1,784 systems to detect anthrax at 284 mail-sorting facilities. The Postal Service will spend $75 million to $100 million annually for Cepheid's devices, which it developed with Northrop Grumman (NYSE:NOC - News). They test the air every hour for harmful particles, notes Piros.
Installation will be finished by 2006, when Piros expects Cepheid to turn profitable. Its bio-defense business alone is worth at least 10 a share, he figures.
Other Cepheid products, including clinical diagnostics for Group B Streptococcus and an antibiotic-resistance test, are worth about 7, he adds. Piros says Cepheid may also be working on a test for animal feed to halt the spread of mad cow disease, using the same technology the Postal Service approved for bio hazards. Cepheid didn't return calls. Al Kildani of C.E. Unterberg, Towbin, says $50 million to $75 million of the Postal Service's funding for bio-threat devices will go to Cepheid itself -- up from his previous estimate of $32 million to $35 million. The rest goes to Northrop. He rates Cepheid a buy for the short and long term.
Truth is stranger than fiction, because fiction has to make sense
NANOPHASE (NANX)
Die Aktie bricht heute um weitere 19,14% auf 12,51 $ aus. Anbei der aktualisierte Wochenchart.
Übergeordnete charttechnische Zielmarke bei 14,2 $.
Es stecken also Chancen drin (vielfach noch sehr nebulös), Risiken (z.B. wird jetzt erst so nach und nach untersucht, wie sich bestimmte z.T. sehr persistente Nanopartikel in der Umwelt, in der Lunge etc. verhalten) und vielfach eine ganz banale Alternative zu bestehenden Produkten und Verfahren, mit denen sie ihre Wettbewerbsfähigkeit unter Marktbedingungen erst beweisen müssen.
Dies ist weder eine Empfehlung noch ein Bash, sondern lediglich der Hinweis darauf, daß ihr es mit einem echten Risiko-Investment-Segment zu tun habt, bei dem man genau wissen sollte, wo man sich mit wieviel Kohle bewegt.
George B. hat Mitte Dezember 2003 3,6 Milliarden locker gemacht für die Nanos, das war halt das Signal.
Gruss E.
New Equipment for Production of Nanoparticles, Microfluidizer Processor Line, and Recent Enhancements Featured in Interview with MFIC CEO, Irwin Gruverman
NEWTON, Mass., Dec 1, 2003 (BUSINESS WIRE) -- At the request of
CEOCFOinterviews.com, Irwin Gruverman, CEO and Chairman of MFIC Corporation
("MFIC" or the "Company") was interviewed by Walter Banks on the subject of
MFIC's line of Microfluidizer(R) materials processing equipment, recent
enhancements to this line, the introduction of a value priced high throughput
production model, and its new, patented, Multiple Stream Mixer Reactor device
for creation of nanoparticles and nanomaterials ("MMR").
MFIC provides leading edge high performance mixing and formulation equipment
available to the biotech, pharmaceuticals, coatings, paint, chemical and food
industries.
The full interview can be found at the Company's website: www.mficcorp.com and
serves to familiarize investors with MFIC, furnishing them insight into the
Company's background, performance, prospects and products while also providing
an update to the October, 2002 interview with the same publisher. The in-depth
interviews conducted by CEOCFOinterviews are geared toward sophisticated
investors who require unbiased, unscripted first-hand perspective to assist them
in making informed investment decisions.
Mr. Gruverman discussed MFIC's Microfluidizer high performance materials
processing equipment, operating at the highest available pressures for high
shear processing of fluids. The uniform, submicron structures created allow
preparation of commercial products having unmatched uniformity, stability and
reliability. Examples include injectable emulsions, ink-jet inks, finish paints,
and soft drinks. In addition, Microfluidizer processors are the standard means
of cell disruption for recovery of proteins produced by biotechnology processes
and are widely used in genomics applications. He also discussed and elaborated
upon the recently introduced MMR for continuous chemical reaction in an
ultraturbulent environment, and emphasized the ability of MMR to efficiently
create production quantities of nanoparticles. This ability will enable the
large-scale applications of these valuable materials. MMR's impact on MFIC's
growth and profitability could be large.
Mr. Gruverman discussed the recent introduction of product enhancements and
features including:
-- M700 Microfluidizer Containment System, which is utilized for
the processing of highly toxic cancer drugs and other
hazardous materials. The first such recently installed system
is now producing pharmaceutical product.
-- M700 Microfluidizer Split System (separating the power source
from the mixing/processing apparatus) accommodates demands of
limited space within clean rooms and for noise abatement
within pharmaceutical production facilities. In conjunction
with this system, a Level II Steam Sterility Option was
introduced for fitting to systems used for production of
injectable and other pharmaceuticals. This option enables
compliance with stringent regulatory production requirements.
We have recently delivered such a system to a pharmaceutical
manufacturer.
-- Ultra Clean in Place (UCIP) option, which improves the ability
to clean in place (CIP) Microfluidizer systems between product
batch runs or before storage. This capability differentiates
our Microfluidizer materials processor systems from all other
competitive products. Several pilot and production systems
incorporating this option have already been delivered.
Mr. Gruverman also discussed the price and competitive advantages of the M710,
MFIC's newest high throughput production system. This system is designed to
materially enhance our competitive position in terms of pricing and performance
in all industries and applications that we serve. In addition to biotechnology
and pharmaceutical production, this product targets markets such as foods,
chemicals and personal care products, by offering pricing that is more
competitive with traditional homogenizers, along with MFIC's superior fluid
processing technology. The M710 systems will improve our margins and delivery
times significantly. More than twelve sales quotations for these systems have
already been made to existing and prospective customers.
Mr. Gruverman also extensively discussed MFIC's patented Multiple Stream
Mixer-Reactor (MMR) system which functions as a continuous chemical reactor.
MFIC believes that MMR technology enables a new unit operation in chemical
engineering practice. The device allows chemical reactions to occur under
ultraturbulent mixing conditions, with no premixing. Such operations are also
known as Collision Reaction Processing. These systems can be configured for
continuous production of nanoparticles. MFIC is proceeding with projects
involving other companies seeking to optimize or enable drug delivery, catalysts
and coatings products, as well as an internal program on nanopolymer creation
for drug delivery and other applications. MFIC expects to deliver the first MMR
laboratory development systems (in the $200,000-$250,000 sales price range) in
2004, with production systems (in the $750,000 - $1,000,000 plus sales price
range) in late 2004 or 2005. The Company believes that it is a leader in the
technology of systems for continuous production of uniform, reproducible,
microparticles, nanoparticles and nanodroplets.
Marketing and sales are centralized and a strong core team leads an extensive
network of agents and distributors in North America, Europe and Asia. About 75%
of Microfluidizer system sales are to the pharmaceutical and biotech industries.
Most sales are to Fortune 500 companies.
Management believes that this release contains forward-looking statements that
are subject to certain risks and uncertainties including statements relating to
the Company's plan to maintain and/or increase operating profitability. Such
statements are based on management's current expectations and are subject to a
number of factors and uncertainties that could cause actual results achieved by
the Company to differ materially from those described in the forward-looking
statements. The Company cautions investors that there can be no assurance that
the actual results or business conditions will not differ materially from those
projected or suggested in such forward-looking statements as a result of various
factors, including but not limited to, the following risks and uncertainties:
(i) whether the performance advantages of the Company's Microfluidizer(R)
materials processing equipment will be realized commercially or that a
commercial market for the equipment will continue to develop, (ii) whether the
Company will have access to sufficient working capital through continued and
improving cash flow from sales and ongoing borrowing availability, the latter
being subject to the Company's ability to comply with the covenants and terms of
the Company's loan agreement with its senior lender, (iii) whether the Company's
expectation that the benefits of nanotechnology will, in part, be realized by
the ability of the MMR to produce innovative materials in large quantities, and
(iv) whether the Company's is able to increase the number of prototype MMR
placements and then manufacture and introduce commercial production MMR
equipment.
MFIC CORPORATION
MFIC Corporation, through its Microfluidics Division, provides patented and
proprietary, high performance Microfluidizer(R) materials processing equipment
to the chemical, pharmaceutical, biotechnology, cosmetic/personal care, and food
processing industries. Through its divisions, the Company provides leading
equipment, and innovative technology and solutions to the chemicals, paints,
pigments and coatings industries for milling, deagglomeration and dissolving.
The combined resources and capabilities of the Company's equipment lines are
used to provide comprehensive solutions for materials processing.
SOURCE: MFIC Corporation
jedoch leider nicht gelistet...vermarkten Forschungsergebnisse in dem Nanotechnologiebereich
Zyvex Dried Film(TM) (ZDF) Carbon Nanotube Solutions, Zyvex Microgrippers, Zyvex NanoSharp(TM) Probes, and Zyvex MEMulator(TM) Software. See details at http://www.zyvex.com/ .
Zyvex's materials and process engineering technology leverages the revolutionary discovery of carbon-based nanostructures with high-volume, composite material production techniques. Zyvex Dried Film (ZDF) removes the "processing bottleneck" for carbon nanotubes -- enabling a wealth of new applications. Zyvex's patent-pending technology disperses and suspends carbon nanotubes in common solvents with unsurpassed concentration and dispersion. ZDF dissolves in common organic solvents and easily mixes with a variety of other materials, creating high-performance composites.
CombiMatrix and Cyrano Sciences Collaborate on the Development of Nanotechnology Based Chemical Sensors
NEWPORT BEACH, Calif., Jan 12, 2004 (BUSINESS WIRE) -- Acacia Research
Corporation (Nasdaq: CBMX) (Nasdaq: ACTG) announced today that its CombiMatrix
Group and Cyrano Sciences will collaborate on the development of chemical
sensors which merge CombiMatrix's microarray technology with Cyrano's electronic
nose technology.
CombiMatrix's arrays incorporate thousands of independently addressable
micro-electrodes on a semiconductor chip. This array technology has been used
for applications in genetic analysis, RNAi drug discovery, biodefense
applications, and nanomaterials discovery. This collaboration seeks to expand
the applicability of this technology for sensing chemical agents in air and
water.
Cyrano Sciences has successfully demonstrated the capability of their array
based nanocomposite sensor technology, more commonly known as an electronic
nose, to detect very low levels of chemicals. "This collaboration merges two
independent nanotechnologies that will have broad impact in chemical detection,"
said Dr. Steven Sunshine, President and CEO of Cyrano Sciences.
"We continue to develop broad applications of our microarray technology," said
Dr. Amit Kumar, President and Chief Executive Officer of CombiMatrix.
"Partnering with Cyrano Sciences offers an opportunity to develop a product for
a new market."
About Cyrano Sciences, Inc.
http://chart.bigcharts.com/bc3/quickchart/...764&mocktick=1&rand=9681
An Nanosys ist TINY als Risikokapitalgeber beteiligt.
Truth is stranger than fiction, because fiction has to make sense
Picks And Axes for Nanotech Gold
John Dobosz, 01.15.04, 10:59 AM ET
NEW YORK - Josh Wolfe, editor of the Forbes/Wolfe
Nanotech Report, strongly recommends buying FEI, the
Hillsboro, Ore.-based supplier of charged particle-beam
systems used in electron microscopes. At $24.56 a share,
FEI trades at the higher end of its 52-week range of $13.55
and $28.75. The company's current market capitalization is
$817 million and it has $252 million in cash; it burned
through $25 million last year. FEIC is highly leveraged, with a
debt/equity ratio of .91.
Although FEI (nasdaq: FEIC - news -
people ) operates in the semiconductor
and data storage markets, Wolfe likes it
for its growing business as a "picks and
axes" player in nanotechnology's
metaphorical "gold rush." FEI's electron
optics business manufactures and
markets scanning electron microscopes
and transmission electron microscopes, used by a growing
number of firms, foundations, and academic institutions
doing nanotechnology research. Last month, President Bush
signed the 21st Century Nanotech Research and
Development Act, which commits $3.7 billion to fund
nanotech research over the next four years.
Several nanotechnology stocks have doubled since
December, including Nanogen (nasdaq: NGEN - news -
people ), Nanophase Technologies (nasdaq: NANX -
news - people ), and nanotech investment firm Harris &
Harris (nasdaq: TINY - news - people ). Altair
Nanotechnologies (nasdaq: ALTI - news - people ) is up
60% in the four weeks since announcing a restructuring to
focus their business on nanotechnology development.
Last July 28, the Oberweis Report recommended
eResearch Technology (ERES) at $17.35 a share in an
email to Stock of the Week subscribers. ERES is up
95% since then. Don't be left behind! Click here to have
Stock of the Week emailed to you on Monday morning.
It's FREE.
Wolfe likes FEIC stock partly because it has lagged the
performance of its peers in both the nanotech tool and
semiconductor capital equipment markets over the past
several months. Wolfe notes that the fourth quarter is
traditionally a seasonally strong one for sales of equipment
to research outfits. In addition, several of FEIC's
semiconductor peers have guided expectations for
fourth-quarter sales higher with positive pre-announcements.
Wolfe is optimistic that the market will value FEIC
significantly higher over the next several months, and he is
confident in the company's future as a supplier to the growing
ranks of nanotechnology researchers.
Truth is stranger than fiction, because fiction has to make sense
Truth is stranger than fiction, because fiction has to make sense
Nanotechnology favorites such as Nanogen Inc. (NGEN), Nanophase Technologies Corp. (NANX) and Veeco Instruments Inc. (VECO) all have doubled, tripled or more during the past year, even though they have no earnings and, for the most part, minimal revenue, according to the WSJ. "We believe nanotechnology could be the next great growth innovation," says John Roy, a Merrill Lynch analyst, who says nanotechnology companies will begin generating revenue and even profit during the next few years. "Like the Internet, nanotech risks being overhyped, but also like the Internet, where there's smoke there's fire." Among the nanotech stocks getting attention right now is Harris & Harris Group (TINY), a New York-based venture-capital fund that counts nanotech companies among its holdings. If anything, the company's ticker symbol -- TINY -- is enough to make short sellers froth. To mitigate the risk, some analysts recommend bigger, more established names such as Veeco and FEI Co. (FEIC), which sell the tools that enable others to use nanotechnology.
Truth is stranger than fiction, because fiction has to make sense
Allerdings wird das voraussichtlich genauso schnell wieder verdrängt und bei der ersten positiven Meldung kommt die nächste Kaufwelle :-)
Unterbewertet, überbewertet spielt hier eh keine große Rolle, da fundamental eigentlich nichts mehr zu den Kursen zu empfehlen ist. Aber wie das mit den Phantasien der Börsianer und den Blasen so ist - kein Grund, dass es nicht weiter geht mit dem Nanohype.
TINY ist übrigens gestern von einem Analysten auf "market perform" herabgestuft worden - was auch immer das heißen mag.
Truth is stranger than fiction, because fiction has to make sense